Purpose: With the recent discovery that ␣-methlyacly-coenzyme A racemase (AMACR) is over expressed in a majority of prostate cancer (CaP) specimens we developed a novel polymerase chain reaction (PCR) based approach that would predict the presence of CaP from prostatic secretions.
Prostate specific antigen (PSA) was first introduced in the 1980s as a serology based prostate cancer (CaP) specific marker. 1, 2 It was believed that PSA would aid in the early detection of CaP and in fact it has led to increased detection of clinically localized disease. 1, 2 However, PSA is not cancer specific because it is expressed similarly by normal, benign and transformed prostatic epithelium. [1] [2] [3] For this reason serum PSA is frequently elevated under conditions that are not related to the presence of CaP, such as trauma, ejaculation, benign prostatic hyperplasia (BPH) and prostatitis. 2 Consequently patients with elevated serum PSA must undergo biopsy to confirm or exclude prostate cancer. Using the standard cutoff value of 4.0 ng/ml PSA screening has sensitivity and specificity in the range of 75% and 30%, respectively. 1 For this reason up to 70% of men who undergo biopsy, as prompted by elevated PSA, are cancer-free. Furthermore, 25% of men with CaP do not show increased serum PSA. 4 Added variations in PSA screening, including age related cutoffs, PSA velocity, PSA density and free PSA, have not yet satisfactorily resolved these concerns. 4 Therefore, an affordable and noninvasive test with high sensitivity and specificity would be expected to circumvent the majority of unnecessary biopsies with the added potential of detecting CaP in patients with otherwise undetectable disease. From this perspective quantitative polymerase chain reaction (PCR) shows almost single cell sensitivity and it can be performed in biological fluids, such as post-massage prostatic secretions. [5] [6] [7] [8] [9] [10] When done under the appropriate conditions, this type of strategy stands to exhibit a high level of diagnostic potential.
Recently ␣-methlyacly-coenzyme A racemase (AMACR) was found to be over expressed in a high majority of CaP tissues compared with normal or benign disease. [11] [12] [13] This discovery prompted us to develop a quantitative reverse transcriptase (RT)-PCR based diagnostic test with the use of this promising new marker. We report a novel approach that involves the quantification of AMACR transcript levels in prostate cells obtained from prostatic secretions following message. PSA transcript levels were then used as a prostate epithelial specific normalizing factor to obtain a relative AMACR value score (RAVS). Our results demonstrate that determining RAVS in prostatic secretions holds great promise as an accurate method for CaP detection. 
METHODS
Sample acquisition. Men attending the urological clinic at our institution were invited to participate. After obtaining informed consent the men underwent prostatic massage. They were then asked to provide a urine specimen of approximately 20 to 50 ml containing the initial portion of the post-massage void. All men with elevated PSA or abnormal digital rectal examination (DRE) underwent transrectal ultrasound guided prostate biopsy. Healthy controls consisted of patients previously shown to present with single or double negative biopsies, or those who were believed to have a reasonable expectation of being disease-free based on age, low PSA and normal DRE. Men with active prostate infections, those on Proscar (Merck and Co., Inc., Whitehouse Station, New Jersey) and those who had recently undergone transrectal prostate resection were excluded.
RNA isolation and PCR. Urine specimens were immediately centrifuged at 500 ϫ gravity for 5 minutes at room temperature. Total RNA was then recovered by transferring the bottom 250 l pellet, which was sometimes barely visible, with a 1.0 ml pipette to a 1.5 ml Eppendorf tube containing 750 l TriReagent (Molecular Research Center, Inc., Cincinnati, Ohio) and isolated according to manufacturer instructions. Purified RNA was reverse transcribed using random hexamer primers (TaqMan Reverse Transcription Kit, Applied Biosystems, Foster City, California). Quantitative RT-PCR was performed on the iCycler Real Time PCR System (BioRad Laboratories, Hercules, California) using primers specific for the AMACR, PSA and TATA binding protein (TBP) transcripts (re-designed from or based on previous reports and at optimized operating temperatures and times (table 1) . 3, 14 Optimization was done for each gene on RNA extracted from the prostate cancer derived LNCaP cell line previously shown to express PSA and AMACR (American Type Culture Collection, Manassas, Virginia). These cells were maintained as reported previously. Dilution curves were then done on viable LNCaP cells diluted in phosphate buffered saline from 10,000 to approximately 1 cell in triplicate. All samples were assayed on 1 plate in duplicate using iQ SYBR Green Supermix (BioRad Laboratories) according to manufacture instructions. Each plate also contained 32 ng control RNA from LNCaP cells in triplicate to ensure that reaction conditions were consistent.
Relative AMACR and PSA transcript levels were determined using the standard ␦ C t method with TBP used as the housekeeping gene to control for differing amounts of starting material. To control further for RNA contributed by prostate epithelial cells the AMACR level was then normalized to that of PSA for each sample. The value generated from this ratio was then multiplied by 100, resulting in what we term RAVS.
Statistics. All statistical calculations, ie mean Ϯ SD and p values, were performed on GraphPad Prism, version 2.0 (GraphPad Software, Inc., San Diego, California).
RESULTS
A total of 30 men were initially enlisted into the current study. However, 6 men were excluded due to recent transurethral prostate resection (3), Proscar use (2) and diagnosed infection (1) . Following RT-PCR another 3 samples were excluded due to insufficient material obtained for analysis.
Therefore, RAVS was calculated for 21 men, including 9 who were healthy, 2 with BPH, 10 with cancer and 2 with high grade PIN (HG-PIN) (table 2). Biopsy confirmation was available on 6 of the 9 patients in the healthy group. The 3 remaining patients were believed to have a reasonable expectation of not harboring occult cancer based on age or a combination of low serum PSA and normal DRE. Patient age was 31 to 77 years in the entire cohort. Prior to running the clinical samples dilution curves were completed using LNCaP cells in phosphate buffered saline with almost single cell detection for each gene under the optimized conditions mentioned and R 2 ϭ Ն 0.97 for the entire range. Initially we were interested in determining if changes in the expression of AMACR or PSA values alone correlated with the presence of CaP ( fig. 1 ). These data indicated that neither AMACR nor PSA alone act as diagnostic predictors of CaP, which is in agreement with previous reports of other genes, including PSA. 6 Conversely by normalizing AMACR to PSA, RAVSs were found to be consistently low in patients in the healthy group (2.7 to 30.9, mean Ϯ SD 15.2 Ϯ 8.5) (fig. 2) . Furthermore, RAVSs were remarkably higher in patients in the CaP group (4.9 to 748.2, mean 189.6 Ϯ 253.2). Using a cutoff score of 32 (2 SD above the mean for normal controls) all healthy controls, including those with BPH but excluding those with PIN, were considered to be correctly diagnosed, thereby, yielding 100% specificity (table 2). One of these men presented with serum PSA greater than 4 ng/ml and 2 had abnormal DRE findings and yet all had negative prostate biopsies. All of these cases were correctly diagnosed as normal with RAVS below 32. In addition, 7 of the 10 patients with cancer were also correctly diagnosed with RAVSs above 32, of whom 1 was found to have Gleason 6 CaP in 6 of 8 biopsy cores and PSA less than 4 ng/ml (that is 2.95). Upon further review of preoperative biopsies 2 patients in the CaP group were found to present with Gleason score 6 (3 ϩ 3), which involved less than 5% of 1 of 12 cores, which may otherwise be considered clinically insignificant disease. 4 In addition, subsequent radical prostatectomy in each patient revealed a single focus of Gleason 6 disease, representing less than 5% of tumor in the entire prostate. RAV scores in these patients was 4.9 to 16.5 (mean 17.4 Ϯ 13.0), leaving only 1 incorrectly diagnosed patient with clinically significant CaP 1 point below the cutoff at 30.9. Therefore, final sensitivity was calculated at 87.5%. Interestingly patents diagnosed with precancerous lesions, that is PIN, were found to have RAVS above the predetermined experimental cutoff value, thus, categorizing them as CaP positive. DISCUSSION AMACR has recently gained attention as a positive histological marker for prostate cancer. 11, [15] [16] [17] [18] Although AMACR is over expressed in prostate cancer, it is also expressed in various tissues, including the liver, brain and kidneys, under normal physiological conditions. 19 In part for this reason it is not likely to be of value as a serum marker for prostate cancer. However, from an alternative perspective prostatic secretions often contain a considerable number of cells shed by the prostate following aggressive prostatic message. 6 Quantitative RT-PCR allows almost single cell detection of genes such as AMACR in a quantitative and reproducible fashion. Indeed, during the initial phase of development of this protocol we found that our quantitative RT-PCR could detect AMACR transcripts almost at the single prostate cancer cell level (LNCaP cells was used established the detection limit). Based on these rationales and preliminary results we measured AMACR transcripts in urine samples following prostatic message. However, a potential problem that we expected to encounter in such an assay was related to the fact that AMACR is expressed in other urogenital cells, such as urothelial cells and renal tubular cells, 19 commonly found in Included 84.6, excluded 100.0 % Sensitivity* Included 76.9, excluded 87.5 Normal patient status determined by age, normal PSA, negative DRE and/or biopsy, patients with HG-PIN were negative for CaP on single 12 core biopsy, 2 with CaP presented with Gleason score 9/10 (all others had Gleason score 6/7 and none had been treated at the time of sample acquisition), 3 with CaP had clinically insignificant disease due to less than 5% CaP in 1 core, positive cores less than 2 and Gleason score less than 6/7, 2 of 9 healthy men presented with BPH, 2 with HG-PIN tested in positive range for CaP and 2 of 10 diagnosed with CaP had clinically insignificant disease.
* Calculated according to standard approach based on correctly and falsely diagnosed patients with sensitivity calculated with and without including patients with HG-PIN in healthy group and sensitivity calculated with and without including patients with nonsignificant cancer in CaP group. urine samples. For this reason it was not surprising to for us to find that the levels of AMACR transcripts alone had no predictive value for CaP due to variations in the composition of various cell types found in the various urine specimens ( fig.  1 ). To overcome this technical hurdle we chose to normalize the level of AMACR transcripts in each sample to that of a normalizing gene to account for the total number of normal and cancerous prostate epithelial cells in each prostate secretion sample. From this perspective since the translatable form of PSA is known to be expressed similarly and specifically in transformed and nontransformed prostatic epithelial cells, it was chosen to be used as a first line candidate for this purpose. 3 Incorporation of this step proved to be crucial to the success of this assay. Although we considered obtaining expressed prostatic secretions directly, our decision to use postmassage urine specimens was based on a decrease in patient discomfort compared with that required for obtaining expressed prostatic secretions.
Our results indicate that using a cutoff RAVS of 2 SD above the mean for the healthy group at 32 a specificity of 100% was demonstrated, thus, indicating that in this healthy group increased serum PSA or abnormal DRE does not appear to adversely affect RAVS. Interestingly 2 patients diagnosed with HG-PIN presented with elevated RAVS above the cutoff, similar to that of the CaP group. This observation was not surprising because it is in agreement with what has been reported at the histological level regarding elevated AMACR in previous studies. 11 In addition, 3 patients with biopsy confirmed prostate cancer had RAVSs within the normal range. However, 2 of these patients were found to have Gleason 6 (3 ϩ 3) disease, representing less than 5% of 1 core. Each patient subsequently went on to radical prostatectomy with gross pathological findings that revealed a single focus of Gleason 6 disease, representing less than 5% of the entire gland. Conversely all patients with RAVSs above the cutoff had biopsies demonstrating high volume and/or high grade disease. Therefore, by categorizing the 2 patients as having clinically insignificant disease, sensitivity was demonstrated at 88.9% with the only misdiagnosed patient having RAVS only 1 point below the cutoff at 31. Finally, further analysis of tumor volumes, serum PSA values and Gleason grade in these patients indicated that there was no correlation with the level of increase in RAVSs.
CONCLUSIONS
The perfect screening test for prostate cancer would avoid unnecessary biopsy in patients without cancer, accurately diagnose those with clinically significant prostate cancer and exclude those with clinically insignificant disease. Although our initial pilot study was somewhat limited in size, our novel technique using quantitative RT-PCR to detect AMACR shows promise as a noninvasive screening test for prostate cancer. Furthermore, early results demonstrate a trend toward excluding patients with clinically insignificant disease that may not yet require aggressive therapy due to a low cancer burden. In the future this technique could be easily adapted for use with any new cancer specific markers identified by the emerging high throughput nanotechnologies, such as microarray screening and proteomics.
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